JP2014524746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524746A5 JP2014524746A5 JP2014520383A JP2014520383A JP2014524746A5 JP 2014524746 A5 JP2014524746 A5 JP 2014524746A5 JP 2014520383 A JP2014520383 A JP 2014520383A JP 2014520383 A JP2014520383 A JP 2014520383A JP 2014524746 A5 JP2014524746 A5 JP 2014524746A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- tumor
- cancer
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 98
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 28
- 102100022763 R-spondin-2 Human genes 0.000 claims description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 108060000903 Beta-catenin Proteins 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000015735 Beta-catenin Human genes 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000004614 tumor growth Effects 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000037841 lung tumor Diseases 0.000 claims description 6
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000023958 prostate neoplasm Diseases 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 3
- 102000047209 human Rspo2 Human genes 0.000 claims description 2
- 229940121396 wnt pathway inhibitor Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 101710174256 Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 91
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 22
- 102100022762 R-spondin-1 Human genes 0.000 description 19
- 230000035772 mutation Effects 0.000 description 16
- 108700001666 APC Genes Proteins 0.000 description 12
- 230000000415 inactivating effect Effects 0.000 description 12
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 description 8
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 6
- 102100022766 R-spondin-3 Human genes 0.000 description 6
- 238000010208 microarray analysis Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 description 4
- 102100022759 R-spondin-4 Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000050526 human RSPO1 Human genes 0.000 description 3
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 2
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 description 2
- 101100531974 Homo sapiens RSPO2 gene Proteins 0.000 description 2
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 description 2
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508403P | 2011-07-15 | 2011-07-15 | |
| US61/508,403 | 2011-07-15 | ||
| US201161521547P | 2011-08-09 | 2011-08-09 | |
| US61/521,547 | 2011-08-09 | ||
| US201161570629P | 2011-12-14 | 2011-12-14 | |
| US61/570,629 | 2011-12-14 | ||
| PCT/US2012/046746 WO2013012747A1 (en) | 2011-07-15 | 2012-07-13 | Rspo binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094648A Division JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524746A JP2014524746A (ja) | 2014-09-25 |
| JP2014524746A5 true JP2014524746A5 (enExample) | 2015-09-03 |
| JP6185463B2 JP6185463B2 (ja) | 2017-08-23 |
Family
ID=47558408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520383A Expired - Fee Related JP6185463B2 (ja) | 2011-07-15 | 2012-07-13 | Ｒｓｐｏ結合剤およびその使用法 |
| JP2017094648A Ceased JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094648A Ceased JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8802097B2 (enExample) |
| EP (2) | EP2731625B1 (enExample) |
| JP (2) | JP6185463B2 (enExample) |
| KR (1) | KR20140048276A (enExample) |
| CN (2) | CN106167526A (enExample) |
| AU (1) | AU2012284254B2 (enExample) |
| BR (1) | BR112014000765A2 (enExample) |
| CA (1) | CA2841745A1 (enExample) |
| CL (1) | CL2014000114A1 (enExample) |
| IL (1) | IL230429A0 (enExample) |
| MX (1) | MX349198B (enExample) |
| RU (1) | RU2014101669A (enExample) |
| WO (1) | WO2013012747A1 (enExample) |
| ZA (1) | ZA201400525B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2093298A3 (en) | 2003-10-10 | 2009-09-23 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins) |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| MX2009003726A (es) | 2006-10-20 | 2009-04-22 | Deutsches Krebsforsch | R-espondinas como moduladores de la angiogenesis y vasculogenesis. |
| HUE027154T2 (en) | 2007-07-02 | 2016-08-29 | Oncomed Pharm Inc | Preparations and procedures for the treatment and diagnosis of cancer |
| WO2011062147A1 (ja) * | 2009-11-17 | 2011-05-26 | 国立大学法人 岡山大学 | 歯髄細胞から象牙芽細胞への分化誘導方法 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| EP2731625B1 (en) | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| AU2013289990B2 (en) | 2012-07-13 | 2018-06-14 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| CA2904337A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| BR112016008477A2 (pt) * | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| CN103724415B (zh) * | 2013-12-31 | 2015-05-27 | 中山大学 | 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用 |
| WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
| EP3180027A4 (en) * | 2014-08-15 | 2018-01-10 | Oncomed Pharmaceuticals, Inc. | Rspo1 binding agents and uses thereof |
| JP2017528523A (ja) * | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2017070567A1 (en) * | 2015-10-21 | 2017-04-27 | The Research Foundation For The State University Of New York | Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections |
| SG11201803359VA (en) * | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
| CN106913880B (zh) * | 2015-12-24 | 2021-02-12 | 上海交通大学 | 一种含有rspo1的靶向给药系统及其制备与应用 |
| IL296874A (en) | 2016-03-01 | 2022-11-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
| CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
| EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
| EP3448875A4 (en) * | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| DK3665198T3 (da) | 2017-08-09 | 2025-04-28 | Merus Nv | Antistoffer, der binder egfr og cmet |
| CN118909118A (zh) | 2017-09-07 | 2024-11-08 | 奥古斯塔大学研究所公司 | 程序性细胞死亡蛋白1抗体 |
| CN109529040B (zh) * | 2017-09-21 | 2020-11-13 | 华东师范大学 | LGR4和R-spondin结合抑制剂及其在肿瘤治疗中的用途 |
| TWI702050B (zh) * | 2017-12-07 | 2020-08-21 | 財團法人國家衛生研究院 | 抗rspo3抗體 |
| CN110339364B (zh) * | 2018-04-02 | 2021-02-12 | 上海邦耀生物科技有限公司 | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 |
| BR112020015999A2 (pt) | 2018-04-06 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos |
| GB201901710D0 (en) * | 2019-02-07 | 2019-03-27 | Nordic Bioscience As | Collagen type 23 assay |
| CN110467663B (zh) * | 2019-06-18 | 2022-05-10 | 华南农业大学 | Rspo3基因在母猪卵巢颗粒细胞中的应用 |
| WO2021022440A1 (zh) * | 2019-08-05 | 2021-02-11 | 北京基石生命科技有限公司 | 肺癌实体瘤原代细胞和肺癌胸腔积液原代肿瘤细胞培养方法及配套试剂 |
| US20230338466A1 (en) * | 2020-06-03 | 2023-10-26 | Children's Hospital Medical Center | Compositions and methods comprising r-spondins for treatment of tumors |
| CN112457400B (zh) * | 2020-12-09 | 2022-03-08 | 福州迈新生物技术开发有限公司 | 抗β-catenin蛋白单克隆抗体、细胞系及其制备方法和应用 |
| CA3243281A1 (en) | 2022-01-28 | 2023-08-03 | Georgiamune Inc | ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1 PD-1 AGONISTS |
| CN116239680B (zh) * | 2023-02-09 | 2024-02-06 | 义翘神州(泰州)科技有限公司 | 猴痘病毒a29小鼠单克隆包被抗体及检测抗体 |
| KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
| KR102551095B1 (ko) * | 2023-03-21 | 2023-07-04 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘2 항체 및 이의 용도 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| CA2288343A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| EP1017811A4 (en) | 1997-09-24 | 2002-08-14 | Merck & Co Inc | HG38 GLYCOPROTEIN HORMONE RECEPTOR COUPLED WITH G-PROTEIN |
| US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| ES2332025T3 (es) | 1998-03-26 | 2010-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina. |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| WO2001088088A2 (en) | 2000-05-18 | 2001-11-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
| DE60044997D1 (de) | 1999-07-02 | 2010-11-04 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| CA2378403A1 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
| CA2399776A1 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001253012B2 (en) | 2000-03-31 | 2006-02-23 | The General Hospital Corporation | Methods of modulating hair growth |
| AU5904101A (en) | 2000-04-05 | 2001-10-23 | Hyseq Inc | Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| EP1290030A2 (en) | 2000-05-30 | 2003-03-12 | Bayer Aktiengesellschaft | Regulation of human lgr4-like g protein-coupled receptor |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6768004B2 (en) | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
| US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
| US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| AU2002304249A1 (en) | 2001-06-11 | 2002-12-23 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
| EP1423428B2 (en) | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| EP2228443A1 (en) | 2001-08-30 | 2010-09-15 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| AU2002342010A1 (en) | 2001-10-03 | 2003-04-14 | Incyte Genomics Inc. | Secreted proteins |
| US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| EP1461023A4 (en) | 2001-12-07 | 2005-08-31 | Univ Michigan | Prospective Identification and Characterization of Breast Cancer Strain Cells |
| CA2469941A1 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| AU2003223124A1 (en) | 2002-04-26 | 2003-11-10 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004074436A2 (en) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
| US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
| CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20050054829A1 (en) | 2003-07-22 | 2005-03-10 | Wiley Steven R. | Compositions and methods relating to TSP-30a, b, c and d |
| DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| EP2093298A3 (en) | 2003-10-10 | 2009-09-23 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins) |
| WO2005040828A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
| JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法 |
| US20050256036A1 (en) | 2004-01-27 | 2005-11-17 | Boyle Bryan J | Gastrointestinal proliferative factor and uses thereof |
| CA2554779A1 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| US7572456B2 (en) | 2004-09-13 | 2009-08-11 | Macrogenics, Inc. | Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof |
| AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| US20090036369A1 (en) | 2005-07-26 | 2009-02-05 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
| US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
| EP1942926A4 (en) | 2005-10-07 | 2010-06-16 | Nuvelo Inc | STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2007053648A2 (en) | 2005-10-31 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| US7659378B2 (en) | 2006-06-02 | 2010-02-09 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| CA2654025C (en) | 2006-06-02 | 2016-08-02 | Xoma Technology Ltd. | Hepatocyte growth factor (hgf) binding proteins |
| ES2413087T3 (es) | 2006-06-13 | 2013-07-15 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el diagnóstico y tratamiento del cáncer |
| US8460667B2 (en) | 2006-07-18 | 2013-06-11 | Sanofi | EPHA2 receptor antagonist antibodies |
| JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| PE20120807A1 (es) | 2006-09-08 | 2012-07-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| MX2009003726A (es) | 2006-10-20 | 2009-04-22 | Deutsches Krebsforsch | R-espondinas como moduladores de la angiogenesis y vasculogenesis. |
| WO2008075796A1 (ja) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
| WO2008088524A2 (en) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| BRPI0812562A2 (pt) | 2007-06-12 | 2019-09-24 | Trubion Pharmaceuticals Inc | composições terapêuticas anti-cd20 e métodos |
| HUE027154T2 (en) | 2007-07-02 | 2016-08-29 | Oncomed Pharm Inc | Preparations and procedures for the treatment and diagnosis of cancer |
| WO2009045443A2 (en) | 2007-10-02 | 2009-04-09 | The University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| JP5676107B2 (ja) | 2007-11-14 | 2015-02-25 | 中外製薬株式会社 | 抗ｇｐｒ４９抗体を用いる癌の診断および治療 |
| US20090186396A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of phosphorylated and nonphosphorylated biomolecules by apatite chromatography |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| BRPI0919473A2 (pt) | 2008-09-26 | 2017-08-29 | Oncomed Pharm Inc | Agentes de ligação frizzled e usos dos mesmos |
| CN103408664B (zh) | 2008-10-31 | 2015-11-25 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
| EP2419133A1 (en) | 2009-04-15 | 2012-02-22 | Deutsches Krebsforschungszentrum | Rspondin-3 inhibition in bone disorders |
| WO2010129284A1 (en) | 2009-04-27 | 2010-11-11 | The Trustees Of The University Of Pennsylvania | Inhibition of hair follicle growth by the wnt inhibitor dkk1 |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CN102695499A (zh) | 2009-06-18 | 2012-09-26 | 惠氏有限责任公司 | 小模块免疫药物的冻干制剂 |
| US8318162B2 (en) | 2009-07-16 | 2012-11-27 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
| WO2011076932A1 (en) | 2009-12-23 | 2011-06-30 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
| WO2011085289A1 (en) | 2010-01-11 | 2011-07-14 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Production of a monoclonal antibody therapeutic against west nile virus in plants |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| AU2011205409B2 (en) | 2010-01-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Wnt-binding agents and uses thereof |
| WO2011100566A2 (en) | 2010-02-12 | 2011-08-18 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| EP2659005A4 (en) | 2010-12-28 | 2016-08-24 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| KR101873614B1 (ko) | 2011-04-28 | 2018-07-02 | 에스비아이 바이오테크 가부시키가이샤 | 항인간 수용체형 단백질 티로신 포스파타아제 σ 항체 |
| EP2731625B1 (en) | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
| WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| RU2014133069A (ru) | 2012-02-11 | 2016-04-10 | Дженентек, Инк. | Транслокации r-спондина и способы с их использованием |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| AU2013289990B2 (en) | 2012-07-13 | 2018-06-14 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| EP2968348A4 (en) | 2013-03-12 | 2016-11-09 | Curegenix Inc | COMPOUNDS FOR THE TREATMENT OF CANCER |
| WO2014192974A1 (ja) | 2013-05-30 | 2014-12-04 | 株式会社オーダーメードメディカルリサーチ | 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬 |
| BR112016008477A2 (pt) | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
-
2012
- 2012-07-13 EP EP12814264.3A patent/EP2731625B1/en active Active
- 2012-07-13 JP JP2014520383A patent/JP6185463B2/ja not_active Expired - Fee Related
- 2012-07-13 EP EP18162940.3A patent/EP3401329A1/en not_active Withdrawn
- 2012-07-13 KR KR1020147003901A patent/KR20140048276A/ko not_active Ceased
- 2012-07-13 MX MX2014000555A patent/MX349198B/es active IP Right Grant
- 2012-07-13 WO PCT/US2012/046746 patent/WO2013012747A1/en not_active Ceased
- 2012-07-13 CN CN201610353524.8A patent/CN106167526A/zh active Pending
- 2012-07-13 US US13/549,050 patent/US8802097B2/en not_active Expired - Fee Related
- 2012-07-13 AU AU2012284254A patent/AU2012284254B2/en not_active Ceased
- 2012-07-13 CA CA2841745A patent/CA2841745A1/en not_active Abandoned
- 2012-07-13 BR BR112014000765A patent/BR112014000765A2/pt unknown
- 2012-07-13 CN CN201280045135.9A patent/CN104023746B/zh not_active Expired - Fee Related
- 2012-07-13 RU RU2014101669/10A patent/RU2014101669A/ru not_active Application Discontinuation
-
2014
- 2014-01-13 IL IL230429A patent/IL230429A0/en unknown
- 2014-01-15 CL CL2014000114A patent/CL2014000114A1/es unknown
- 2014-01-22 ZA ZA2014/00525A patent/ZA201400525B/en unknown
- 2014-06-27 US US14/318,253 patent/US9109025B2/en not_active Expired - Fee Related
- 2014-06-27 US US14/318,247 patent/US9109024B2/en not_active Expired - Fee Related
-
2015
- 2015-07-09 US US14/795,811 patent/US9644034B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/480,081 patent/US20170298143A1/en not_active Abandoned
- 2017-05-11 JP JP2017094648A patent/JP2017169578A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524746A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP2022071038A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達を破壊することによる癌免疫療法 | |
| JP7368856B2 (ja) | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 | |
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2022068352A (ja) | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法 | |
| ES2877757T3 (es) | Tratamiento terapéutico de cáncer de mama basado en el estado de c-MAF | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| KR20160024391A (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2013512278A5 (enExample) | ||
| WO2012149246A1 (en) | Methods of treating squamous cell carcinoma related applications | |
| JP2019517498A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 | |
| JP2019520034A5 (enExample) | ||
| TW201642897A (zh) | Ｈｅｒ２結合劑治療 | |
| US20210246219A1 (en) | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof | |
| CN112292151B (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| CN118871467A (zh) | 抗pd-l2抗体 | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| KR20220100099A (ko) | 위암의 검출 및 치료를 위한 조성물 및 방법 | |
| WO2016168634A1 (en) | Biomarkers related to treatment of cancer with her3 and egfr inhibitors | |
| CA3169455A1 (en) | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |